LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Brain Swelling versus Infarct Size: A Problematizing Review.

    Simard, J Marc / Wilhelmy, Bradley / Tsymbalyuk, Natalya / Shim, Bosung / Stokum, Jesse A / Evans, Madison / Gaur, Anandita / Tosun, Cigdem / Keledjian, Kaspar / Ciryam, Prajwal / Serra, Riccardo / Gerzanich, Volodymyr

    Brain sciences

    2024  Volume 14, Issue 3

    Abstract: In human stroke, brain swelling is an important predictor of neurological outcome and mortality, yet treatments to reduce or prevent brain swelling are extremely limited, due in part to an inadequate understanding of mechanisms. In preclinical studies on ...

    Abstract In human stroke, brain swelling is an important predictor of neurological outcome and mortality, yet treatments to reduce or prevent brain swelling are extremely limited, due in part to an inadequate understanding of mechanisms. In preclinical studies on cerebroprotection in animal models of stroke, historically, the focus has been on reducing infarct size, and in most studies, a reduction in infarct size has been associated with a corresponding reduction in brain swelling. Unfortunately, such findings on brain swelling have little translational value for treating brain swelling in patients with stroke. This is because, in humans, brain swelling usually becomes evident, either symptomatically or radiologically, days after the infarct size has stabilized, requiring that the prevention or treatment of brain swelling target mechanism(s) that are independent of a reduction in infarct size. In this problematizing review, we highlight the often-neglected concept that brain edema and brain swelling are not simply secondary, correlative phenomena of stroke but distinct pathological entities with unique molecular and cellular mechanisms that are worthy of direct targeting. We outline the advances in approaches for the study of brain swelling that are independent of a reduction in infarct size. Although straightforward, the approaches reviewed in this study have important translational relevance for identifying novel treatment targets for post-ischemic brain swelling.
    Language English
    Publishing date 2024-02-28
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2651993-8
    ISSN 2076-3425
    ISSN 2076-3425
    DOI 10.3390/brainsci14030229
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery.

    Quinlan, John A / Inglut, Collin T / Srivastava, Payal / Rahman, Idrisa / Stabile, Jillian / Gaitan, Brandon / Arnau Del Valle, Carla / Baumiller, Kaylin / Gaur, Anandita / Chiou, Wen-An / Karim, Baktiar / Connolly, Nina / Robey, Robert W / Woodworth, Graeme F / Gottesman, Michael M / Huang, Huang-Chiao

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

    2024  Volume 11, Issue 17, Page(s) e2302872

    Abstract: Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy ( ... ...

    Abstract Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or inducing biological changes. PDT can ablate unresectable GBM and sensitize tumors to chemotherapy. Verteporfin (VP) is a promising photosensitizer that relies on liposomal carriers for clinical use. While lipids increase VP's solubility, they also reduce intracellular photosensitizer accumulation. Here, a pure-drug nanoformulation of VP, termed "NanoVP", eliminating the need for lipids, excipients, or stabilizers is reported. NanoVP has a tunable size (65-150 nm) and 1500-fold higher photosensitizer loading capacity than liposomal VP. NanoVP shows a 2-fold increase in photosensitizer uptake and superior PDT efficacy in GBM cells compared to liposomal VP. In mouse models, NanoVP-PDT improved tumor control and extended animal survival, outperforming liposomal VP and 5-aminolevulinic acid (5-ALA). Moreover, low-dose NanoVP-PDT can safely open the blood-brain barrier, increasing drug accumulation in rat brains by 5.5-fold compared to 5-ALA. NanoVP is a new photosensitizer formulation that has the potential to facilitate PDT for the treatment of GBM.
    MeSH term(s) Animals ; Photochemotherapy/methods ; Verteporfin/pharmacology ; Verteporfin/therapeutic use ; Mice ; Photosensitizing Agents/administration & dosage ; Photosensitizing Agents/pharmacology ; Brain Neoplasms/drug therapy ; Drug Delivery Systems/methods ; Glioblastoma/drug therapy ; Nanoparticles/chemistry ; Disease Models, Animal ; Humans ; Rats ; Liposomes ; Cell Line, Tumor ; Brain/metabolism ; Brain/drug effects
    Chemical Substances Verteporfin (0X9PA28K43) ; Photosensitizing Agents ; Liposomes
    Language English
    Publishing date 2024-03-06
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2808093-2
    ISSN 2198-3844 ; 2198-3844
    ISSN (online) 2198-3844
    ISSN 2198-3844
    DOI 10.1002/advs.202302872
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top